Trial record 1 of 1 for:    NCT01211691
Previous Study | Return to List | Next Study

Study of KB004 in Subjects With Hematologic Malignancies

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by KaloBios Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
KaloBios Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01211691
First received: September 24, 2010
Last updated: June 4, 2014
Last verified: June 2014
  Purpose

This is a global, multicenter, open-label, repeat-dose, Phase 1/2 study consisting of a Dose Escalation Phase (Phase 1) and a Cohort Expansion Phase (Phase 2). In both phases, KB004 will be administered by IV infusion once weekly as part of a 21-day dosing cycle.


Condition Intervention Phase
Acute Myeloid Leukemia (AML)
Acute Lymphocytic Leukemia (ALL)
Chronic Myelogenous Leukemia (CML)
Chronic Lymphocytic Leukemia (CLL)
Myelodysplastic Syndrome (MDS)
Myeloproliferative Neoplasms (MPN)
Myelodysplastic/Myeloproliferative Neoplasm Overlap
Multiple Myeloma (MM)
Myelofibrosis (MF)
Drug: KB004, Monoclonal Antibody
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects With EphA3-Expressing Hematologic Malignancies

Resource links provided by NLM:


Further study details as provided by KaloBios Pharmaceuticals:

Primary Outcome Measures:
  • Phase 1: Determine a possible maximum tolerated dose (MTD) [ Time Frame: Once weekly for the first three weeks of study treatment ] [ Designated as safety issue: Yes ]
  • Phase 2: To characterize preliminary clinical activity based on the International Working Group (IWG) criteria specific to the hematologic malignancy [ Time Frame: Evaluations at designated timepoints ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Phase 1: Examine clinical activity [ Time Frame: Evaluations at designated timepoints ] [ Designated as safety issue: No ]
  • Phase 1/2: Safety and Tolerability [ Time Frame: Duration of study participation ] [ Designated as safety issue: Yes ]
  • Phase 1/2: Pharmacokinetic profile [ Time Frame: Cycle 1: multiple timepoints. Thereafter, single samples at designated cycles ] [ Designated as safety issue: No ]
  • Phase 1/2: Assess immunogenicity [ Time Frame: Cycle 1: multiple timepoints. Thereafter, single samples at designated cycles ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 150
Study Start Date: September 2010
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Phase 1 dose levels: KB004

IV infusion 1x Weekly for a 21 day dosing cycle

Subjects with heme malignancies will be assigned to one of 11 planned KB004 (dose levels (20mg, 40mg, 70mg, 100mg, 140mg, 190mg, 250mg, 330mg, 440mg, 590mg, and 700mg)

Drug: KB004, Monoclonal Antibody
Experimental: Phase 2 dose levels: KB004

IV infusion 1x Weekly for a 21 day dosing cycle

Subjects with AML or MDS will be assigned to one of two planned KB004 dose levels (20mg or recommended Phase 2 dose)

Drug: KB004, Monoclonal Antibody

Detailed Description:

The purpose of Phase 1 is to determine a maximum tolerated dose (MTD) for KB004 when administered to subjects with hematologic malignancies who meet the entry criteria.

The purpose of Phase 2 is to characterize preliminary clinical activity. The Phase 2 portion of the study consists of two parts:

  • Part A: Subjects with AML or MDS who meet the entry criteria
  • Part B: (Not yet open)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria (Phase 1):

- Confirmed hematologic malignancy, including Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPN) or MDS/MPN overlap diseases. (Once Phase 2 has started subjects with AML will be eligible for inclusion in the Phase 1 portion of the study only if their malignancy has been shown to have c-Cbl mutation, trisomy 3, trisomy 11, inv(16), or elevated FLT3. [Other AML and subjects with MDS will no longer be eligible for inclusion in the Phase 1 portion of the study]).

Key Inclusion Criteria (Phase 2):

  • Part A: AML or MDS with an acceptable level of EphA3 expression
  • Part B: (Not yet open)

Key Inclusion Criteria (Both Phases):

  • Confirmed hematologic malignancy refractory to or progressed following standard treatments, or subjects not considered medically suitable to receive standard of care treatment or who refuse standard of care treatment
  • Acceptable level of EphA3 expression
  • Eastern Cooperative Oncology Group (ECOG) ≤1
  • Acceptable laboratory results

Key Exclusion Criteria (Both Phases):

  • Previously treated AML subjects, length of first complete remission less than 3 months
  • History of or current central nervous system (CNS) involvement that may increase risk of bleeding
  • Recent major surgery
  • Ongoing surgical or wound healing complications
  • Active clinically significant bleeding
  • Uncontrolled hypertension
  • Significant intercurrent illness
  • Known history of prolonged bleeding times or platelet dysfunction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01211691

Contacts
Contact: Clinical Trials clinicaltrials@kalobios.com

Locations
United States, California
Recruiting
Palo Alto, California, United States, 94304
Not yet recruiting
Sacramento, California, United States, 95817
United States, Florida
Recruiting
Miami, Florida, United States, 33136
Recruiting
Tampa, Florida, United States, 33612
United States, Missouri
Withdrawn
St. Louis, Missouri, United States, 63110
United States, Ohio
Recruiting
Cleveland, Ohio, United States, 44195
United States, Texas
Recruiting
Houston, Texas, United States, 77030
Australia, New South Wales
Recruiting
Westmead, New South Wales, Australia, 2145
Australia, South Australia
Recruiting
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Recruiting
Prahran, Victoria, Australia, 3007
Australia, Western Australia
Withdrawn
Perth, Western Australia, Australia, 6000
Australia
Recruiting
Queensland, Australia, 4006
Sponsors and Collaborators
KaloBios Pharmaceuticals
Investigators
Study Chair: Nestor A. Molfino, MD, MSc KaloBios Pharmaceuticals
  More Information

No publications provided

Responsible Party: KaloBios Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01211691     History of Changes
Other Study ID Numbers: KB004-01
Study First Received: September 24, 2010
Last Updated: June 4, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by KaloBios Pharmaceuticals:
Hematologic
Leukemia
Malignancies
Myeloproliferative Neoplasms

Additional relevant MeSH terms:
Primary Myelofibrosis
Neoplasms
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multiple Myeloma
Neoplasms, Plasma Cell
Myelodysplastic Syndromes
Preleukemia
Myeloproliferative Disorders
Hematologic Neoplasms
Myelodysplastic-Myeloproliferative Diseases
Bone Marrow Diseases
Hematologic Diseases
Neoplasms by Histologic Type
Leukemia, B-Cell
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hemorrhagic Disorders

ClinicalTrials.gov processed this record on July 28, 2014